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Flavonoids from Pterogyne nitens 
Inhibit Hepatitis C Virus Entry
Jacqueline Farinha Shimizu1,2, Caroline Sprengel Lima3, Carina Machado Pereira1, Cintia Bittar1, 
Mariana Nogueira Batista1, Ana Carolina Nazaré3, Carlos Roberto Polaquini3, Carsten Zothner4, 
Mark Harris  4, Paula Rahal1, Luis Octávio Regasini3 & Ana Carolina Gomes Jardim1,2
Hepatitis C virus (HCV) is one of the leading causes of liver diseases and transplantation worldwide. The 
current available therapy for HCV infection is based on interferon-α, ribavirin and the new direct-acting 
antivirals (DAAs), such as NS3 protease and NS5B polymerase inhibitors. However, the high costs of 
drug design, severe side effects and HCV resistance presented by the existing treatments demonstrate 
the need for developing more efficient anti-HCV agents. This study aimed to evaluate the antiviral 
effects of sorbifolin (1) and pedalitin (2), two flavonoids from Pterogyne nitens on the HCV replication 
cycle. These compounds were investigated for their anti-HCV activities using genotype 2a JFH-1 
subgenomic replicons and infectious virus systems. Flavonoids 1 and 2 inhibited virus entry up to 45.0% 
and 78.7% respectively at non-cytotoxic concentrations. The mechanism of the flavonoid 2 block to 
virus entry was demonstrated to be by both the direct action on virus particles and the interference on 
the host cells. Alternatively, the flavonoid 1 activity was restricted to its virucidal effect. Additionally, no 
inhibitory effects on HCV replication and release were observed by treating cells with these flavonoids. 
These data are the first description of 1 and 2 possessing in vitro anti-HCV activity.
Hepatitis C virus (HCV) was identified in 1989 as the causative agent of hepatitis C1. It infects millions of people 
worldwide and is the major cause of liver disease and transplantation. According to World Health Organization 
(WHO), more than 350,000 people die currently from liver disease related to HCV infection2.
HCV is an enveloped, single stranded positive-sense RNA virus, which belongs to the Flaviviridae fam-
ily, genus Hepacivirus3. There is no effective vaccine for prevention of the HCV infection and, until recently, 
the only treatment for HCV infected patients was based on pegylated interferon and ribavirin association 
(PEG-IFN + RBV)4. The availability of new direct acting antivirals (DAAs) such as simeprevir, daclatasvir and 
sofosbuvir have increased rates of sustained virological response (SVR) with treatment efficacies as high as 90% 
for most common HCV genotypes5–8. However, the current treatments present several side effects, high costs9 
and resistant variants were described even for the recent therapies approved by Food and Drugs Administration 
(FDA)10,11. Therefore, despite the introduction of interferon-free regimens, the therapy regime in many countries 
is still based on PEG-IFN + RBV.
The high costs and potential for developing viral resistance presented by the existing treatments demonstrate 
the need for improving therapeutic options against HCV. In this context, natural sources have demonstrated to 
provide a wide source of compounds, which can be evaluated for their antiviral properties12.
Flavonoids represent an important class of compounds, which are produced by plants as a response to 
microbial infections13. Several flavonoids have been described to possess antiviral activities. Epigallocatechin 
from green tea was demonstrated to inhibit replication of Enterovirus 7114, Chikungunya virus15 and HCV16. 
Naringenin from grapefruit showed antiviral effects against Herpes simplex virus type 1 (HSV-1)17 and HCV18. 
Silibin and ladanein have also demonstrated anti-HCV activities by inhibiting the viral entry step19,20. In this 
context, the high structural similarity between ladanein and flavonoids from Pterogyne nitens Tul. (Leguminosae) 
and other active flavonoids encouraged us to search for their potential anti-HCV activity by inhibition of viral 
entry.
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Pterogyne nitens, popularly named, as “bálsamo”, “cocal”, “amendoim-bravo” and “yvi-raró”, is the unique 
member of its genus21. Ethnopharmacological studies in Guarani indigenous communities from Argentina 
indicated that cold aqueous preparations from its stem barks have been used for the treatment of helmin-
thic infestations, mainly against Ascaris lumbricoides22. Chemically, this species presents a variety of bioactive 
metabolites, including guanidine alkaloids23, triterpenes and steroids24. Phenolic compounds isolated from 
flowers showed myeloperoxidase inhibitory (MPO) and radical scavenging activities25. Studies with flavo-
noids from this plant have demonstrated their antiproliferative effect against melanoma cells26, inhibition of 
MPO27,28, radical scavenging properties and antioxidant activities29–32, as well as a potent antifungal activity 
against opportunistic fungi33.
Thus, the aim of this study was to investigate the effects of sorbifolin (1) and pedalitin (2) from P. nitens on 
HCV cycle. The data obtained displayed that these compounds strongly inhibited HCV entry to the hepatocytes 
by either the direct action on virus particles or the interference on the hepatocytes, but had no effect on virus 
replication and release.
Results
Anti-HCV activity of Sorbifolin and Pedalitin. To evaluate the anti-HCV activity of the flavonoids 1 and 
2 from P. nitens leaves (Fig. 1A), cytotoxicity screening of these compounds in näive Huh-7.5 cells was carried 
out. Cells were treated with increasing doses of each compound for 72 hours, and cell viability was measured 
by the MTT assay. The same assay was performed with Huh-7.5 cells infected with JFH-1 HCVcc and the anti-
viral activity of compounds was measured by luminescence levels. The results showed a tolerance of Huh-7.5 
cell lines under treatment with both compounds which decreased HCV infectivity in a dose-dependent manner 
(Fig. 1B). The effective (EC50) and cytotoxic concentration (CC50) was determined for both compounds (37.93 
and 113.3 µM for compound 1; 51.97 and 113.6 µM compound 2). Therefore, further assays were performed for a 
better understand of their antiviral activity.
Figure 1. Flavonoids from Pterogynes nitens. The structure of sorbifolin (1) and pedalitin (2) (a). Cell viability 
and virus infectivity of flavonoids in näive Huh-7.5 cell line, cells were treated with compounds (1) and (2) 
at two-fold dilution 500 to3.9 µM for 72 h (b). DMSO 0.1% was used as non-treated control. Mean values of 
experiments are shown.
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We also evaluated the ability of the compounds to inhibit an alternative genotype of HCV.
To do this we used the full-length intergenotypic recombinant HCV genotype 3a/2a S52/JFH-1 replicon, 
which contains the core to NS2 protein regions from S52 replicon and the 5′UTR and NS3 protein to 3′UTR 
regions from JFH-1 replicon34. Cells were infected with HCVcc genotype 3a/2a S52/JFH-1 and immediately 
treated with each compound for 72 hours. Our results demonstrated that the compounds 1 and 2 also blocked the 
HCVcc S52/JFH-1 infectivity up to 81 and 66,25%, respectively (P < 0,001) (Fig. 2). These data corroborate with 
genotype 2a inhibitory rates, demonstrating the anti-HCV genotype-independent activity of these compounds.
Sorbifolin and Pedalitin inhibit HCV entry to the host cells. To analyse the effects of compounds 1 
and 2 on HCV entry to the host cells, virus-containing inoculum and compounds at 50 µM were simultaneously 
added to Huh7.5 cells and incubated for 4 hours. Cells were extensively washed with PBS to remove any remain-
ing virus or compounds, and replaced with fresh medium for 72 hours. The intracellular virus was titrated by 
using a focus formation unit assay. The results demonstrated that 1 and 2 were able to block HCV entry up to 
45.0%and 78.7%, respectively (Fig. 3A).
To further investigate the inhibitory activity of compounds 1 and 2 on virus entry, supernatant containing 
JFH-1 HCVcc was incubated with 50 μM of each compound for 1 hour at 37 °C prior to the infection of Huh-7.5 
cells. The inoculum of virus and compound were transferred to the naïve cells and incubated for 4 hours. Cells 
were washed for the complete removal of the inoculum and replaced with fresh media for 72 hours when virus 
was titrated. A significant virucidal activity was observed for both compounds 1 and 2 which blocked 38.2% and 
86% of virus entry, respectively (p < 0.001) (Fig. 3B). These data suggest that an anti-HCV mechanism of action 
for these compounds might be related to a direct action on the virus particle structure.
We also investigated whether the antiviral activity of these compounds was related to their effects on host cells. 
For this, Huh-7.5 cells were pre-treated with the compounds for 1 hour at 37 °C, followed by washes with PBS to 
remove any trace of compounds, prior to infection with JFH-1 HCVcc virus for 4 hours. Supernatant was replaced 
by fresh media after further PBS washes and intracellular virus was titrated at 72 hpi. The analysis showed that the 
flavonoid 2 significantly inhibited infectivity when cells were previously treated with this compound, blocking 
72.5% of virus entry (Fig. 3C). On the other hand, compound 1 was not able to inhibit HCV entry by the prior 
treatment of cells. In addition to the above data, these results suggest that compound 2 seems to act on both the 
virus particle and the host cells.
Sorbifolin and Pedalitin showed no effect on HCV replication or release. Flavonoids were also 
described to inhibit other steps of HCV life cycle, for example the blockage of genome replication by api-
genin35 and xanthohumol36, and the interference with virus release by naringenin18,37. The effects of the flavo-
noids 1 and 2 on HCV replication were evaluated using a firefly luciferase HCV subgenomic replication system 
(SGR-FEO-JFH-1)38. Huh7.5 cells stably harboring the SGR-FEO-JFH-1 were treated with varying concentra-
tions of the compounds from 0.4–50 μM and incubated for 72 h to assess both the cytotoxicity and antiviral 
effects. Cell viability and HCV replication levels were measured by MTT and luciferase assays, respectively. The 
results showed that non-cytotoxic concentrations of 1 and 2 had no effect on HCV replication (Fig. 4).
The effect of 1 and 2 on HCV release was evaluated by the quantification of intra and extra-cellular virus RNA 
using qPCR. Neither compound showed any inhibition of HCV release (Fig. 5) since there was no significant 
difference between intra and extracellular HCV RNA levels after 24 h of treatment.
Sorbifolin and Pedalitin did not synergistically inhibit HCV when combined with Sofosbuvir. To 
evaluate whether compounds 1 and 2 enhance the anti-HCV activity of clinically used anti-HCV drugs. Huh-7.5 
cells were infected with JFH-1 HCVcc and immediately treated with sub-EC50 concentrations of compounds 1 
Figure 2. Inhibitory effect of compounds 1 and 2 against HCV genotype 3. Huh-7.5 cells were infected with 
S52/JFH-1 HCVcc and compounds at 50 μM concentration were immediately added to cells. The intracellular 
virus was titrated 72 h.p.i. by analyzing focus-forming units per milliliters (FFU/mL). DMSO 0.1% was used as 
non-treated control. P < 0.01 vs DMSO was considered significant.
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(10 µM), 2 (20 µM) and Sofosbuvir (0.6 µM) in monotherapy or in combined treatments. Our results showed that 
as monotherapy, compounds 1, 2 and Sofosbuvir inhibited 36.2%, 38% and 33.4% of HCV, respectively. In com-
bined treatment, compound 1 plus Sofosbuvir inhibited 49.6% and compound 2 plus Sofosbuvir inhibited 62.7% 
(Fig. 6). Although, a slight increase in HCV inhibition has been observed, no statistically significant differences 
were observed between combined treatments and the monotherapies (P < 0.001). All treatments were considered 
statistically different from the DMSO control (P < 0.001).
Figure 3. Effects of (1) and (2) on HCV infectivity. Infectious supernatant and compounds were added at 
different times to the cells, and the intracellular virus was titrated 72 h post-infection by analyzing focus-
forming units per milliliters (FFU/mL). The percentage of infection was calculated using as reference the DMSO 
non-treated control. For entry assay, Huh-7.5 cells were infected with JFH-1 HCVcc and compounds 1 and 2 
were immediately added. After 4 h, the supernatant was removed and replaced with fresh medium after repeated 
washes with PBS to remove the inoculum (a). For virucidal assay, JFH-1 HCVcc were incubated with (1) or (2) 
for 1 h prior to the infection. After that, the inoculum was used to infect naïve Huh-7.5 cells for 4 h. Cells were 
exhaustively washed and medium replaced (b). In the pre-treatment assay, cells were previously treated with 
compounds (1) and (2) for 1 h prior to the infection. Cells were washed to remove compounds and infected 
with JFH-1 virus for 4 h. Supernatants were removed, cells were washed to complete virus removal and were 
incubated with fresh media for up to 72 h post-infection (c). DMSO 0.1% was used as non-treated control and 
EGCG was used as control for entry blockade. Mean values of three independent experiments each measured in 
triplicate including the standard deviation are shown. P < 0.001 vs DMSO was considered significant.
Figure 4. Effect on HCV replication. Huh-7.5 cells stably harboring subgenomic replicon SGR-FEO-JFH-1 
were treated with (1) (a) and (2) (b) at 50, 10, 2 and 0.4 µM for 72 h. Cell viability (▴) and replication (●) 
were evaluated by MTT and luciferase assays, respectively. DMSO 0.1% was used as non-treated control and 
cyclosporine A (CsA) at 1 µM was used as control of inhibition of replication. Mean values of experiments are 
shown and P < 0.001 vs DMSO was considered significant.
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Discussion
Our results demonstrated that the flavonoids Sorbifolin and Pedalitin isolated from Brazilian natural plants were 
able to block HCV entry to the host cells in a genotype independent manner. These data corroborate with previ-
ous findings concerning the activity of flavonoids on virus entry. In 2012, Calland et al. showed that the flavonoid 
EGCG was a potent HCV entry inhibitor16. More recently, delphinidin was identified as having potent activity 
against HCV entry, and it was shown that the mechanism of entry blockage observed for EGCG and delphinidin 
were the alteration in the structure of the HCV viral particles caused by these compounds, preventing the virus 
from binding to the cells39. Another mechanism of action was observed to silibinin, a flavonoid reported to block 
the HCV post-attachment step by altering clathrin mediated endocytosis and endosomal trafficking, resulting 
in a protective effect on host cells20. Anggakusuma et al. verified the anti-HCV activity of curcumin, a natural 
phenolic compound that inhibits HCV entry of all major genotypes by affecting virion envelope fluidity and by 
preventing HCV cell-to-cell transmission. By using quantum chemical and chemometric methods, Souza et al. 
demonstrated semi-empirically the predicted potential activity of three flavones on picornavirus particles40. Haid 
et al. isolated ladanein from Marrubium peregrinum, a flavone with potent and broad-spectrum antiviral activity 
against the entry of all HCV genotypes into human hepatocytes.
Erlejman et al. also demonstrated that the protective effects of flavonoids on cell membranes were mainly 
associated to a higher number of hydroxyl groups present in the molecules which is also related to their hydro-
philicity and interactions between flavonoids and lipid bilayers41. Therefore, the biological activities of flavonoids 
were often associated with the types and number of functional radical groups in the chemical structure of differ-
ent compounds42,43.
The structural difference between flavonoids 1 and 2 is a single radical, since flavonoid 2 the differences 
observed in the anti-HCV activity of flavonoids 1 and 2 could be explained.
Figure 5. The capacity of compounds 1 and 2 to inhibit HCV release. Huh-7.5 cells previously infected with 
JFH-1 virus were plated 48 h prior treatment. Compounds (1) or (2) were added at 50 μM and incubated for 
24 h. Supernatant was collected and cells were harvested, and intra and extracellular RNA were quantified 
by qPCR. DMSO 0.1% was used as non-treated control and naringenin (NR) at 400 μM was used as positive 
control of HCV secretion. Mean values of two independent experiments each measured in triplicate including 
the standard deviation are shown. ***P < 0.005 vs extracellular. ***P < 0.001 vs DMSO.
Figure 6. Effect of compounds 1 and 2 in monotherapy or combined with Sofosbuvir. Huh-7.5 cells were 
infected with JFH-1 HCVcc and compounds at specific concentration were immediately added to cells. After 
72 h, cell viability (a) and virus infectivity (b) were measured. Compound 1, 2 and Sofosbuvir (SOF) were 
tested at 10 µM, 20 µM and 0.6 µM, respectively. DMSO was used as non-treated control. P < 0.01 vs DMSO was 
considered significant (***).
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The latest advance in therapy against HCV is the development of the DAAs, which target the replication step. As 
result, it succeeded in decreasing the viral replication and improved SVR rates44. However, due to an error-prone 
RNA polymerase and lack of proofreading in HCV45, as well the natural presence of virus quasispecies46, resistant 
variants to the current available HCV treatment have been reported47,48. Drug combination therapy is consid-
ered to be a promising approach to increase therapeutic efficacy and decrease drug resistance in comparison with 
mono-drug therapy49. However, compounds 1 and 2 did not synergistically inhibited HCV when combined with 
Sofosbuvir. Although these flavonoids did not enhance DAAs activity, new therapeutical approaches which target 
further stages of the HCV lifecycle cycle are necessary. These compounds were able to block viral entry and thus 
have demonstrated potent antiviral activity, making them an interesting target for future therapies against HCV 
since they could prevent virus infection at a very early stage in the virus replicative cycle.
In summary, the results showed that flavonoids from P. nitens inhibited HCV entry in vitro. Further analyses 
are necessary clarify the mechanisms of these flavonoids act against HCV infection. To the best of our knowl-
edge, this is the first description of flavonoids from P. nitens leaves, which were screened against HCV in vitro 
and demonstrated antiviral effect by blocking entry stage of HCV cycle. The compounds 1 and 2 were previously 
documented to be isolated from other plant species, including Ruellia tuberosa50, Mentha pulegium, and M. sua-
veolens51. However, no antiviral activity was described. Therefore, these finds may be useful for the future devel-
opment of new anti-HCV approaches.
Methods
Phytochemical Procedures. Leaves of P. nitens were collected in the Institute of Biosciences, Letters 
and Exact Sciences, São Paulo State University (UNESP), São José do Rio Preto, SP, Brazil (20°47′02.4′′S 
49°21′36.0′′W) in July 2014. A voucher specimen (10291) was deposited in the Herbarium of Ilha Solteira (HISA) 
of the Faculty of Engineering, University of São Paulo State (Unesp), Ilha Solteira, SP, Brazil. The shade-dried 
leaves (630 g) was ground in a knife grinder and extracted twice (48 h, room temperature) by maceration with 
ethanol. The solvent was removed by filtration resulting in the ethanol extract. Ethanol extract (10 g) was submit-
ted to reversed-phase C-18 silica gel CC (22 × 5 cm) eluted with ethanol: water gradient, affording 13 fractions of 
300 mL each (L1‒L13), which were combined after comparison of their TLC profile [ethyl acetate: water: formic 
acid: acetic acid (100:27:11:11)] revealed with anisaldehyde-sulphuric acid reagent. Fraction L8 (412 mg) was 
subjected to gel permeation column chromatography using Sephadex® LH-20 (100 × 3 cm), eluted with ethanol 
to afford 60 subfractions of 30 mL each (SL1‒SL60). All the subfractions were compared by TLC profile using 
[ethyl acetate: water: formic acid: acetic acid (100:27:11:11)] revealed with anisaldehyde-sulphuric acid reagent. 
Subfractions SL31‒SL36 (50 mg) and SL44‒SL53 (70 mg) presented one spot on TLC plates, suggesting purifica-
tion of compounds 1 and 2, respectively. Subfractions SL37‒SL43 demonstrated mixture of 1 and 2. Structures of 
compounds 1 and 2 were identified by comparison with literature data, mainly 1H and 13C NMR values52–54. The 
MR spectra were obtained in DMSO-d6 solution, using a Varian INOVA 500 spectrometer (11.7 T), operating at 
500 MHz for 1H and 125 MHz for 13C. Sorbifolin (1): TLC Rf 0.57 [ethyl acetate: water: formic acid: acetic acid 
(100:27:11:11)], 1H NMR δH (multiplicity; J in Hz; position): 12.5 (br s 5-OH), 3.87 (s; 7-OCH3), 7.89 (d; 8.5; H-2′ 
and H-6′), 6.90 (d; 8.5; H-3′ and H-5′), 6.85 (s; H-8), 6.70 (s; H-3). 13C NMR δc (position): 182.5 (C-4), 154.7 
(C-7), 150.1 (C-9), 164.3 (C-2), 161.4 (C-4′), 116.4 (C-3′ and C-5′), 102.8 (C-3), 121.7 (C-1′), 105.3 (C-10), 130.2 
(C-6), 91.5 (C-8), 128.8 (C-2′ and C-6′), 146.4 (C-5). Pedalitin (1): TLC Rf 0.34 [ethyl acetate: water: formic acid: 
acetic acid (100:27:11:11)], 1H NMR δH (multiplicity; J in Hz; position): 12.6 (br s; 5-OH), 3.92 (s; 7-OCH3), 7.44 
(d; 1.5; H-2′), 7.43 (dd; 1.5 and 8.5; H-6′), 6.90 (d; 8.5; H-5′), 6.85 (s; H-8), 6.68 (s; H-3). 13C NMR δc (position): 
182.0 (C-4), 154.3 (C-7), 149.6 (C-9), 163.9 (C-2), 149.6 (C-4′), 145.7 (C-3′), 115.9 (C-3′), 102.5 (C-3), 121.7 
(C-1′), 105.0 (C-10), 129.9 (C-6), 91.0 (C-8), 113.4 (C-2′) and 118.8 (C-6′).
Partition coefficient (n-octanol/water) measured by HPLC method. The partition coefficient was cal-
culated using the HPLC method according procedures described by OECD Guidelines for the Testing of Chemicals52. 
The equipment used was a Shimadzu HPLC model CBM 20-A (Shimadzu®) equipped with photodiode array 
detector (model SPD-M20A), binary pumping system mobile phase (model LC-20ADXR), solvent degasser (model 
DGU-20A3R), injector system (model SIL-20AC) and a Gemini C-18 chromatographic column (Phenomenex®, 
250 mm × 4.6 mm, 5 μm, 100 Å). For HPLC method was used an isocratic mode [methanol:water (3:1)] and 1.0 mL/
min. The sample volume injected was 20 µL and the wavelength was 354 nm. The following substances were used as 
references to construct the curve log K × log P: thiourea, aniline, phenol, acetophenone and benzoic acid. The capacity 
factor (log K) of the compounds was determined from their retention times and interpolated in linearity curve log 
K × log P. The partition coefficient (Log Po/w) of flavonoids 1 and 2 was 1.6 and 1.3, respectivily (Figure S1).
Sample Preparation. The lyophilized compounds were dissolved in dimethyl sulfoxide (DMSO) in stock 
solutions and stored at −80 °C. Compounds were diluted in complete medium immediately prior to the experi-
ments to reach a maximum final concentration of 0.1% DMSO. For all the assays performed, non-treated control 
was added of DMSO at the same final concentration. Epigallocatechin-gallate (EGCG, Sigma-Aldrich) was used 
as positive control for entry, pre-treatment and virucidal assays15,16,55. Cyclosporine A (CsA) was used as positive 
control of inhibition of replication56,57.
HCV Replicons. Antiviral activity of compounds was evaluated by using both subgenomic and full-length 
HCV replicon systems. The full-length HCV genotype 2a JFH-158 and intergenotypic recombinant HCV geno-
type 3a/2a S52/JFH-159 replicons were used to perform virus assays as described below. The subgenomic replicon 
SGR-FEO-JFH-1, based on the non-structural proteins NS3-NS5B of HCV genotype 2a JFH-1 strain inserted of a 
firefly luciferase-neomycin phosphotransferase fusion protein, was used to performed replication assay38.
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Cell Culture. The human hepatocyte cell line Huh-7.5 (Apath LLC, Brooklyn, NY) was maintained in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma–Aldrich) supplemented with 100 U/mL penicillin (Gibco 
Life Technologies), 100 mg/mL streptomycin (Gibco Life Technologies), 1% non-essential amino acids (Gibco 
Life Technologies), 1% HEPES (Gibco Life Technologies, USA) and 10% fetal bovine serum (FBS; Cultilab) at 
37 °C in a humidified 5% CO2 incubator. Huh-7.5 cells stably harboring the SGR-FEO-JFH-1 were cultured under 
the same condition, added of 500 µg/mL of G418 (Sigma-Aldrich, USA).
Cell Viability. Cell viability was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide] (Sigma–Aldrich) assay. Huh-7.5 or SGR-FEO-JFH-1 Huh-7.5 cells were seed in 96-well microplates 
and incubated at 37 °C in a humidified 5% CO2 incubator overnight. Drug-containing medium at different con-
centrations was added to the cell culture. After incubation for 72 hours, DMEM containing MTT at1 mg/mL was 
added to each well, incubated for 1 hour and replaced with 100 μL of DMSO to solubilize the formazan crystals. 
The absorbance was measured at 562 nm on a plate reader (FLUOstar Omega/BMG LABTECH, Offenburg, BW, 
DE). Cell viability was calculated according to the equation (T/C) × 100%, which T and C represented the mean 
optical density of the treated and control groups, respectively. DMSO was used as non-treated control. The cyto-
toxic concentration of 50% (CC50) was calculated using Prism (Graph Pad).
Luciferase-based Replication. Huh-7.5 cells stably harboring the SGR-FEO-JFH-1 were seeded on 
96-well plates at a density of 5 × 103 per well and compounds at 50 µM, 10 µM, 2 µM and 0.4 µM were added. After 
72 hours, cells were harvested by lysis with Passive Lysis Buffer (Promega) and HCV RNA replication was quanti-
fied by measuring luminescence levels using the Luciferase Assay System (Promega) and a plate reader (FLUOstar 
Omega/BMG LABTECH, Offenburg, BW, DE).
Virus assays. HCVcc particles were generated as described previously60. Briefly, 8 × 106 Huh-7.5 cells were 
electroporated with 10 μg of JFH-158 or S52/JFH-1 RNA59 and infectious supernatant was collected from after 
48 hours incubation. Naïve Huh7.5 cells were seeded the day before the assay was carried out. Cells were infected 
with JFH1cc virus58 at a multiplicity of infection (MOI) of 0.4 and compounds at specific concentrations were 
added at different times, depending on the stage of HCV cycle to be evaluated. The effective concentration of 50% 
(EC50) was calculated using Prism (Graph Pad).
Inhibitory Effects on Entry Steps. For virus entry experiments, JFH-1 HCVcc was used to infect Huh-
7.5 cells in complete medium with compounds for 4 hours. The supernatant plus virus was removed, cells were 
washed three times with PBS to completely remove the inoculum, replaced with fresh complete medium and 
incubated at 37 °C in a humidified 5% CO2 incubator. After 72 hours, the supernatant was removed, cells were 
fixed and intracellular virus was titrated.
Pre-treatment assay. Huh-7.5 cells were pre-treated with each compound for 1 hour at 37 °C in a humid-
ified 5% CO2 incubator prior to the infection. After incubation, cells were washed extensively to remove 
compounds and were infected with HCVcc JFH-1 virus for 4 hours. Infectious supernatant was removed, addi-
tional washes were performed to virus removal and fresh media was added. The virus was titrated 72 hours 
post-infection (hpi).
Virucidal assay. For virucidal assay, infectious supernatant containing HCVcc JFH-1 virus was incubated 
with each compound for 1 hour at 37 °C prior to the infection. Then, the mixture was used to infect naive Huh-
7.5 cells for 4 hours at 37 °C in a humidified 5% CO2 incubator. The inoculums were removed, cells were washed 
three times with PBS, replaced by fresh media and incubated 72 hours at 37 °C in a humidified 5% CO2 incubator. 
Virus was titrated 72 hpi.
Virus Titration. Cells were fixed with 4% para-formaldehyde (PFA) 72 hpi, washed with 100 mM Glycine 
(Applichem), semi-permeabilized with 0.1% Triton X-100 (Vetec Labs) and stained for NS5A using sheep 
anti-NS5A61 and Alexa Fluor anti-sheep 594 secondary antibody. Infectivity was expressed as focus-forming 
units per milliliter of supernatant (FFU/mL).
HCV Release/Assembly Assessment. To analyze the compounds 1 and 2 influence on HCV secretion, 
2 × 105 JFH-1 infected cells were seeded 48 hours before treatment. Then, the medium was replaced by fresh 
medium supplemented with compounds at 50 μg/mL as described by Nahmias et al.37. DMSO 0,1% was used 
as non-treated control and Naringenin (NR) at 400 μM was used as control of HCV secretion inhibition37. After 
24 hours of incubation, RNA was extracted from the supernatant and from the cells using TRIzol reagent (Life 
Technologies, Carlsbad, CA, USA), and cDNA was synthesized with High-Capacity cDNA Archive (Applied 
Biosystems, Foster City, CA, USA). HCV expression analysis was performed by TaqMan Universal PCR Master 
Mix no AmpErase UNG (Applied Biosystems, Branchburg, NJ, USA) detecting the amplification of the HCV 
5′UTR region (Forward: CGGGAGAGCCATAGTGG; Reverse: AGTACCAACAAGGCCTTTCG). The samples 
quality and normalization of levels of expression were obtained by amplification of the endogenous gene GAPDH. 
JFH1 release inhibition was calculated as a percentage of negative control.
Combined Treatment with Sofosbuvir. Huh-7.5 cells were infected with JFH-1 HCVcc and treated 
immediately with compound 1 (10 µM), 2 (20 µM) and Sofosbuvir (0.6 µM) (SOVALDI®) in monotherapy 
or combined treatments. After 72 hours, cell viability and infection levels were measured. DMSO was used as 
non-treated control.
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Statistical Analysis. Individual experiments were performed in triplicate and all assays were performed 
a minimum of three times in order to confirm the reproducibility of the results. Differences between means of 
readings were compared using analysis of variance (One-way or Two-way ANOVA) and Students t test. P values 
of less than 0.05 (indicated by asterisks) were considered statistically significant.
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